{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:59:25Z","timestamp":1791583165207,"version":"4.3.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/bor.0b013e3283456797","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T00:08:36Z","timestamp":1300838916000},"page":"273-277","source":"Crossref","is-referenced-by-count":61,"title":["The value of blocking IL-6 outside of rheumatoid arthritis: current perspective"],"prefix":"10.1097","volume":"23","author":[{"given":"Miho","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"R2-10-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.10620","article-title":"Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease","volume":"46","author":"Iwamoto","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/s10165-008-0116-2","article-title":"A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years","volume":"19","author":"Nakahara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10067-010-1553-9","article-title":"A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature","volume":"29","author":"Perdan-Pirkmajer","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-010-1418-2","article-title":"Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab","volume":"29","author":"Sumida","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","article-title":"Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"61","author":"Tanaka","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"J Immunol"},{"key":"R16-10-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.1992.tb03042.x","article-title":"Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression","volume":"88","author":"Kitani","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"R17-10-20210128","first-page":"16","article-title":"Urinary levels of IL-6 in patients with active lupus nephritis","volume":"40","author":"Iwano","year":"1993","journal-title":"Clin Nephrol"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","article-title":"IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/W F1 mice","volume":"112","author":"Mihara","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clim.2004.03.023","article-title":"Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile","volume":"112","author":"Saiki","year":"2004","journal-title":"Clin Immunol"},{"key":"R20-10-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.100.1.55","article-title":"Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?","volume":"100","author":"Noris","year":"1999","journal-title":"Circulation"},{"key":"R21-10-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","article-title":"Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis","volume":"45","author":"Park","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/01.CIR.93.10.1788","article-title":"Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis","volume":"93","author":"Seko","year":"1996","journal-title":"Circulation"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/000331979204300610","article-title":"Distinct responses of interleukin-6 and other laboratory parameters to treatment in a patient with polyarteritis nodosa: a case report","volume":"43","author":"Nakahama","year":"1992","journal-title":"Angiology"},{"key":"R24-10-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000163802","article-title":"In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease","volume":"61","author":"Koch","year":"1993","journal-title":"Pathobiology"},{"key":"R25-10-20210128","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"J Clin Invest"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J Dermatol Sci"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/ard.53.9.574","article-title":"Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjogren's syndrome","volume":"53","author":"Gudbjornsson","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"R28-10-20210128","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"J Rheumatol"},{"key":"R29-10-20210128","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/art.10177","article-title":"Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis","volume":"46","author":"Straub","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e3283456797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:04:39Z","timestamp":1786043079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201105000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283456797","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}